Selecting antihypertensive medication in patients with essential hypertension in Malaysia

Medical Journal of Malaysia

Volumn 64, Issue 1, 2009, Pages 3-11

  Ong, Hean Teik ^a   Rozina, G ^b  

^a HT Ong Heart Clinic   (Malaysia)

^b Penang Adventist Hospital   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ATENOLOL; BENAZEPRIL; BENDROFLUMETHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TRANDOLAPRIL; VALSARTAN; VERAPAMIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MALAYSIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; HUMANS; HYPERTENSION; MALAYSIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70449711270     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. UK Prospective Diabetes Study Group. Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
2. Hansson L, Lindholm LH, Niskanen L, et al. Effect of ACE inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP). Lancet 1999; 353: 611-6.
3. Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 (STOP-Hypertension 2) study. Lancet 1999; 354: 1751-56.
4. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
5. Hansson L, Hedner T, Lund-Johansen P, et al for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and ,-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet 2000; 356: 359-65.
6. Dahlof B, Devereux RB, Kjeldsen SE, et al for the LIFE study group. Cardiovascular morbidity and mortality in the losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertesnive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003; 42: 239-46.
9. Wing LMH, Reid CM, Ryan P, et al for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin coverting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-92.
10. Black HR, Elliott WJ, Grandits G, et al for the CONVINCE Research Group. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular End points (CONVINCE) trial. JAMA 2003; 289: 2073-82.
11. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290: 2805-16.
12. Julius S, Kjeldsen SE, Weber M, for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-31.
13. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin-converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181-91.
14. Dahlof B, Sever PS, Poulter NR, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as require versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
15. Jamerson K, Weber MA, Bakris GL, et al for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Engl J Med 2008; 359: 2417-28.
16. Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension. Compelling science or commercial speech? JAMA 2006; 295: 1704-6.
17. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167-70.
18. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 2006; 295: 2270-74.
19. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-75.
20. Barzilay JI, Davis BR, Bettencourt J, et al for the ALLHAT Collaborative research Group. Cardiovascular outcomes using doxazosin vs chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders : a report from the ALLHAT Study. J Clin Hypertens 2004; 6: 116-25.
21. Whelton PK, Barzilay J, Cushman WC, et al for the ALLHAT Collaborative Research group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern med 2005; 165: 1401-9.
22. Rahman M, Pressel S, Davis BR, et al for the ALLHAT Collaborative Research Group. Renal Outcomes in High-Risk Hypertensive Patients Treated with an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: a Report from the ALLHAT Study. Arch Inten Med 2005; 165: 936-46.
23. Wright JT, Dunn JK, Cutler JA, et al for the ALLHAT Collaborative Research Group. Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril. JAMA 2005; 293: 1595-607.
24. HT Ong. The JNC 7 Hypertension guidelines. JAMA 2003; 290: 1312.
25. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886-92.
26. Pahor M, Guralnik JM, Corti M-C, et al Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43:1191-97.
27. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
28. Shinoda E, Yui Y, Kodama K, et al. Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension 2005; 45: 1153-8.
29. Nissen SE, Tuzcu EM, Libby P, for the CAMELOT investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study : a randomized controlled trial. JAMA 2004; 292: 2217-26.
30. Pitt B, Byington RP, Furberg CD, for the PREVENT investigators. Effect of amlodipine on the progression of atherosclerosis and occurrence of clinical events. Circulation 2000; 102: 1503-10.
31. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-51.
32. Poulter NR, Wedel H, Dahlof B, for the ASCOT investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-13.
33. Daviglus ML, Liu K. Today's Agenda. We must focus on achieving favorable levels of all risk factors simultaneously. Arch Intern Med 2004; 164: 2086-87.
34. Duerden M. ASCOT-BPLA. Lancet 2006; 367: 206.
35. Cave JA. ASCOT: A tale of two treatment regimes. Is ASCOT all it's cracked up to be? BMJ 2005; 331: 1023.
36. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy due to Type 2 Diabetes. N Engl J Med 2001; 345:851-60.
37. Parving HH, Lehnert H, Mortensen JB, et al. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes. N Engl J Med 2001; 345: 870-78.
38. Brenner BM, Cooper ME, Zeeuw D de, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med 2001; 345: 861-69.
39. Beri T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138: 542-49.
40. Agodoa LY, Appel L, Bakris GL, et al for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001; 285: 2719-28.
41. Wright JT, Bakris G, Greene T, et al for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288: 2421-31.
42. UK prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
43. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684-89.
44. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174: 1737-42.
45. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension ? A meta-analysis. Lancet 2005; 366: 1545-53.
46. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
47. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-88.
48. PROGRESS collaborative group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-41.
49. The PEACE Trial Investigators. Angiotensin-Converting Enzyme Inhibition in stable Coronary Artery Disease. N Engl J Med 2004; 351: 2058-68.
50. Nissen SE, Tuzcu EM, Libby P, for the CAMELOT investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA 2004; 292: 2217-26.
51. Mochizuki S, Dahlof B, Shimizu M, et al for the JIKEI Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (JIKEI Heart Study): a randomized, open-label, blinded end-point morbidity-mortality study. Lancet 2007; 369: 1431-39.
52. The telmisartan randomised assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372: 1174-83.
53. Yusuf S, Diener HC, Sacco RL, et al for the PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225-37.
54. The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
55. Mann JFE, Schmeider RE, McQueen M, et al on behalf of the ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372: 547-53.
56. National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care: pharmacological update. London: Royal College of Physicians, 2006. Available at: www.nice.org.uk/ CG034guidance
57. Mancia G, de Backer G, Dominiczak A, et al for the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28: 1462-536.
58. Ong HT. Beta-blockers in hypertension and cardiovascular disease. BMJ 2007; 334: 946-9.
59. Khan MG. Beta-blocker controversies. In: Khan MG. Cardiac Drug Therapy (7th Ed). New Jersey: Humana Press Inc, 2007: 37-42.
60. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation 2006; 113: 1213-25.
61. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684-89.
62. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension ? A meta-analysis. Lancet 2005; 366: 1545-53.
63. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174: 1737-42.
64. Benetos A, Waeber B, Izzo J, et al. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness. Am J Hypertens 2002; 15: 1101-8.
65. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart study. Circulation 1997; 96: 308-15.
66. Resnick LM, Lester MH. Differential effects of antihypertensive drug therapy on arterial compliance. Am J Hypertens 2002; 15: 1096-100.
67. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. bmj.com 2009; doi:10.1136/bmj.39548.738368.BE.
68. Bangalore S, Sawhney S, Messerli FH. Relation of Beta-Blocker-Induced Heart Rate Lowering and Cardioprotection in Hypertension. J Am Coll Cardiol, 2008; 52: 1482-89.
69. Reil JC, Bohm M. BEAUTIFUL results - the slower, the better? Lancet 2008; 372: 779-80.
70. Chamberlain DA. The medical treatment of angina pectoris. Br Heart J 1987; 58: 547-51.
71. Freemantle N, Cleland J, Young P, Manson J, Harrison J. Beta blockade after myocardial infarction ; systematic review and meta-regression analysis. BMJ 1999; 318: 1730-7.
72. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low dose Metoprolol CR/XL and Fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-blocker Cholesterol- lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-26.
73. Sipahi I, Yuzcu M, Wolski KE, et al. Beta-blockers and progression of coronary atherosclerosis: Pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 2007; 147: 10-18.
74. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353: 9-13.
75. PackerM, Coats AJS, Fowler MB, et al for the Carvedilol Prospective Randomised Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J med 2001; 344: 1651-8.
76. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
77. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-67.
78. COMMIT (Clopidrogel and metoprolol in myocardial infarction trial) collaborative group. Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 36: 1622-32.
79. Liu L, Wang JG, Gong L, et al for the Systolic Hypertension in China (Sys-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823-29.
80. Staessen JA, Fagard R, Thijs L, et al for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.
81. Guidelines Committee. Clinical Practice Guidelines: Management of hypertension (3rd Edition). Putrajaya: Ministry of Health, Academy of Medicine, Society of Hypertension, Malaysia; 2008.
82. Pfeffer MA, Braunwald E,Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327: 669-77.
83. Pfeffer MA, McMurray JJV, Velazques EJ, et al. Valsartan, captopril or both in myocardial infarctioncomplicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
84. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 372: 685-91.
85. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2006.
86. Messerli FH, Grossman E, Lever AF. Do thiazide diuretics confer specific protection against strokes? Arch Intern Med 2003; 163: 2557-60.
87. Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension. J Am Coll Cardiol 2002; 39: 315-22.
88. Chobanian AV, Bakris GL, Black HR, et al and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-72.
89. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organisation (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92.
90. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-35.
91. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-76.
92. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24: 1193-1200.
93. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005; 19: 607-13.
94. Williams B. Treating hypertension: it is not how you start but where you end that matters. J Hypertens 2003; 21: 455-7.
95. Yusuf S. Preventing vascular events due to elevated blood pressure. Circulation 2006; 113: 2166-8.
96. Connor J, Rafter N, Rodgers A. Do fixed dose combination pills or unit of use packaging improve adherence? A systematic review. Bull World Health Organ 2004; 82: 935-9.
97. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008; 300: 2514-26.
98. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2006: 40: 15-20.